Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution

Journal of Gene Medicine

Volumn 12, Issue 6, 2010, Pages 516-527

  Li, Xiong ^a   Liu, Youhong ^a   Tang, Yong ^b   Roger, Phipps ^a   Jeng, Meei Huey ^c   Kao, Chinghai ^c  

^a Maine Institute for Human Genetics & Health   (United States)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; CMV promoter; Docetaxel; Gene therapy; Oncolytic adenovirus; p38 MAPK

Indexed keywords

DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE P38; BETA1 INTEGRIN; BETA3 INTEGRIN; TAXOID;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; EX VIVO STUDY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSGENE; TUMOR GROWTH; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; ADENOVIRIDAE; ANIMAL; CANCER TRANSPLANTATION; CELL DEATH; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROMOTER REGION; PROSTATIC NEOPLASMS; REPORTER GENE; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD29; CELL DEATH; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTEGRIN BETA3; MALE; NEOPLASM TRANSPLANTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; TAXOIDS; TRANSGENES; VIRUS REPLICATION;

EID: 77954616958     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1462     Document Type: Article

References (42)

1. Beardsley EK, Chi KN. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 2008; 2: 161-166.
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520. (Pubitemid 39315318)
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl JMed 2004; 351: 1502-1512.
4. Friedland D, Cohen J, Miller R Jr, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999; 26: 19-23.
5. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999; 26: 14-18.
6. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346-358.
7. Kumar S, Gao L, Yeagy B, et al. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008; 10: 371-379.
8. Freytag SO, Kim JH, Brown SL, et al. Gene therapy strategies to improve the effectiveness of cancer radiotherapy. Expert Opin Biol Ther 2004; 4: 1757-1770.
9. Green NK, Seymour LW. Adenoviral vectors: systemic delivery and tumor targeting. Cancer Gene Ther 2002; 9: 1036-1042.
10. Li X, Zhang YP, Kim HS, et al. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Res 2005; 65: 1941-51.
11. Lee SJ, Kim HS, Yu R, et al. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther 2002; 6: 415-421.
12. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000; 19: 6660-6669.
13. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-6747.
14. Li X, Liu YH, Lee SJ, et al. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Clin Cancer Res 2008; 14: 291-299.
15. Li X, Liu YH, Zhang YP, et al. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin Cancer Res 2007; 13: 5463-5473.
16. Ahn M, Lee SJ, Li X, et al. Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther 2009; 16: 73-82.
17. Yu DC, Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525.
18. Gleave M, Hsieh JT, Gao CA, et al. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991; 51: 3753-3761.
19. Kelly KJ, Sandoval RM, Dunn KW, et al. A novel method to determine specificity and sensitivity of the TUNEL reaction in the quantitation of apoptosis. Am J Physiol Cell Physiol 2003; 384: C1309-C1318.
20. Weibel ER. Stereological Methods. Practical Methods for Biological Morphometry. Academic Press: New York, 1980; 40-160.
21. Hemminki A, Belousova N, Zinn KR, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001; 4: 223-231. (Pubitemid 32851286)
22. Stamminger T, Fickenscher H, Fleckenstein B. Cell type-specific induction of the major immediate early enhancer of human cytomegalovirus by cyclic AMP. J Gen Virol 1990; 71: 105-113. (Pubitemid 20046015)
23. Egami T, Ohuchida K, Mizumoto K, et al. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake. Clin Cancer Res 2008; 14: 1859-1867.
24. Kim KI, Kang JH, Chung JK, et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med 2007; 48: 1553-1561.
25. Bruening W, Giasson B, Mushynski W, et al. Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. Nucleic Acids Res 1998; 26: 486-489.
26. Svensson RU, Barnes JM, Rokhlin OW, et al. Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res 2007; 67: 10445-10454.
27. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007; 7: 141-148.
28. Lopez CA, Kimchi ET, Mauceri HJ, et al. Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther 2004; 3: 1167-1175.
29. You L, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 2000; 60: 1009-1013.
30. Freytag SO, Barton KN, Brown SL, et al. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 2007; 15: 1600-1606.
31. Freytag SO, Stricker H, Peabody J, et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007; 15: 636-642.
32. Nielsen LL, Lipari P, Dell J, et al. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 1998; 4: 835-846. (Pubitemid 28183383)
33. Sanchez-Prieto R, Quintanilla M, Cano A, et al. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1 A gene. Oncogene 1996; 13: 1083-1092.
34. Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
35. Debbas M, White E. Wild-type p53 mediates apoptosis by E1 A, which is inhibited by E1B. Genes Dev 1993; 7: 546-554.
36. AbouEl Hassan MA, Braam SR, Kruyt FA. Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells. Cancer Gene Ther 2006; 13: 1105-1114.
37. Libertini S, Iacuzzo I, Perruolo G, et al. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res 2008; 14: 6505-6514.
38. McKee TD, Grandi P, Mok W, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 2509-2513.
39. Nagano S, Perentes JY, Jain RK, et al. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res 2008; 68: 3795-3802.
40. Seidman MA, Hogan SM, Wendland RL, et al. Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle. Mol Ther 2001; 4: 13-21.
41. Li Y, Okegawa T, Lombardi DP, et al. Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents. J Urol 2002; 167: 339-346.
42. Hingorani M, White CL, Zaidi S, et al. Radiation-mediated upregulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin Cancer Res 2008; 14: 4915-4924.